Discordance between power Doppler and DAS28 assessment of remission induction in a randomised, placebo-controlled stud of infliximab therapy in early rheumatoid arthritis

Discordance between power Doppler and DAS28 assessment of remission induction in a randomised, placebo-controlled stud of infliximab therapy in early rheumatoid arthritis

Detalhes bibliográficos
Main Authors:	Taylor, P, Steuer, A, McClinton, C, Blomley, M, Wagner, C, Marsters, P, Maini, R
Formato:	Conference item
Publicado em:	2005

Registos relacionados

Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis.
Por: Taylor, P, et al.
Publicado em: (2004)

Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiological evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis.
Por: Taylor, P, et al.
Publicado em: (2003)

Comparison of remission induction in erosive early KA assessed by DAS28 calculated using either ESR or CRP in infliximab plus MTX combination therapy or MTX monotherapy
Por: Taylor, P, et al.
Publicado em: (2005)

Kinetics of change in erosion scores as assessed by plain radiography and high frequency ultrasound in a randomised, controlled trial of infliximab plus MTX versus MTX only therapy in erosive early rheumatoid arthritis
Por: Taylor, P, et al.
Publicado em: (2005)

Comparison of ultrasonographic measures of synovitis and radiographic assessment of structural damage over two years in a randomised, controlled trial of infliximab therapy in erosive early rheumatoid arthritis.
Por: Taylor, P, et al.
Publicado em: (2004)

Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis.
Por: Taylor, P, et al.
Publicado em: (2006)

JOINT DESTRUCTION IS ATTENUATED BY INFLIXIMAB IN EARLY RA PATIENTS WITH ULTRASONOGRAPHIC MARKERS OF POOR PROGNOSIS
Por: Taylor, P, et al.
Publicado em: (2003)

Infliximab attenuates joint destruction in early RA patients with ultrasonographic markers of poor prognosis.
Por: Taylor, P, et al.
Publicado em: (2002)

Ultrasonographic and radiographic evidence of attenuated joint destruction in early RA patients treated with infliximab
Por: Taylor, P, et al.
Publicado em: (2003)

Ultrasonographic evidence of attenuated joint destruction within 18 weeks in early RA patients treated with infliximab.
Por: Taylor, P, et al.
Publicado em: (2003)

Association between radiographic progression and persistent vascular signal on power doppler imaging in early rheumatoid arthritis
Por: Taylor, P, et al.
Publicado em: (2006)

SIGNIFICANT CHANGES IN SONOGRAPHIC MEASURES OF JOINT VASCULARITY AND SERUM VEGF IN EARLY RA PATIENTS ON INFLIXIMAB BY 18 WEEKS OF THERAPY
Por: Taylor, P, et al.
Publicado em: (2002)

High frequency power Doppler ultrasound reveals hypervascular erosions are common in early rheumatoid arthritis
Por: Steuer, A, et al.
Publicado em: (2001)

Combined power color Doppler and greyscale ultrasound demonstrate an association between vascularity and erosions in rheumatoid arthritis.
Por: Steuer, A, et al.
Publicado em: (2000)

Quantitative power Doppler and greyscale ultrasound demonstrate an association between vascularity and erosions in early rheumatoid arthritis
Por: Steuer, A, et al.
Publicado em: (2001)

How does infliximab work in rheumatoid arthritis?
Por: Maini, R, et al.
Publicado em: (2002)

Infliximab and methotrexate in the treatment of rheumatoid arthritis
Por: Lipsky, P, et al.
Publicado em: (2000)

Infliximab for the treatment of rheumatoid arthritis.
Por: Blumenauer, B, et al.
Publicado em: (2002)

Early RA patients on infiliximab therapy show significant changes in sonographic measures of joint vascularity and serum VEGF by 18 weeks.
Por: Taylor, P, et al.
Publicado em: (2001)

Infliximab in the therapy of rheumatoid arthritis
Por: G. V. Lukina, et al.
Publicado em: (2016-05-01)

Prevalence of subjective voice impairment in rheumatoid arthritis.
Por: Fisher, B, et al.
Publicado em: (2008)

Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis.
Por: Maini, R, et al.
Publicado em: (1999)

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
Por: Charles, P, et al.
Publicado em: (2000)

INFLIXIMAB (REMICADE): POSSIBILITIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Por: Nataliya Vladimirovna Chichasova, et al.
Publicado em: (2011-03-01)

EFFICACY OF INFLIXIMAB IN THERAPY OF REFRACTORY JUVENILE RHEUMATOID ARTHRITIS (JRA)EFFICACY OF INFLIXIMAB IN THERAPY OF REFRACTORY JUVENILE RHEUMATOID ARTHRITIS (JRA)
Por: E.I. Alexeeva, et al.
Publicado em: (2006-03-01)

EFFICACY OF INFLIXIMAB IN THERAPY OF REFRACTORY JUVENILE RHEUMATOID ARTHRITIS (JRA)EFFICACY OF INFLIXIMAB IN THERAPY OF REFRACTORY JUVENILE RHEUMATOID ARTHRITIS (JRA)
Por: E.I. Alexeeva, et al.
Publicado em: (2006-01-01)

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
Por: Lipsky, P, et al.
Publicado em: (2000)

Early infliximab trough levels in paediatric IBD patients predict sustained remission
Por: Nanja Bevers, et al.
Publicado em: (2024-01-01)

HOW IS THE DIET QUALITY OF PATIENTS WITH CROHN’S DISEASE IN CLINICAL REMISSION USING INFLIXIMAB?
Por: Melissa Mercadante Santana CRUZ, et al.
Publicado em: (2021-10-01)

Ultrasound remission in patients with rheumatoid arthritis in clinical remission
Por: Rym Fakhfakh, et al.
Publicado em: (2021-12-01)

Remissão de retículo-histiocitose multicêntrica com terapia combinada com infliximabe Remission of multicentric reticulohistiocytosis with combined terapy witb infliximab
Por: Sílvia Arroyo Rstom, et al.
Publicado em: (2008-12-01)

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
Por: Maini, R, et al.
Publicado em: (1999)

Stabilization of Bilateral Progressive Rheumatoid Corneal Melt with Infliximab
Por: Sheelah F. Antao, et al.
Publicado em: (2012-01-01)

Infliximab treatment in a case of rheumatoid scleromalacia perforans
Por: R. Herrera-Esparza, et al.
Publicado em: (2011-06-01)

Ultrasound of metacarpophalangeal joints is a sensitive and reliable endpoint for drug therapies in rheumatoid arthritis: results of a randomized, two-center placebo-controlled study.
Por: Seymour, M, et al.
Publicado em: (2012)

Incidence and management of infusion reactions to infliximab in 186 italian patient’s with rheumatoid arthritis: the Padua experience
Por: S. Todesco, et al.
Publicado em: (2011-09-01)

Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn’s disease
Por: Kouzhu Zhu, et al.
Publicado em: (2024-08-01)

Remission of Cap Polyposis Maintained for More Than Three Years after Infliximab Treatment
Publicado em: (2009-12-01)

EXPERIENCE OF TREATMENT WITH ABATACEPT IN CHILD WITH JUVENILE RHEUMATOID ARTHRITIS AND SECONDARY INEFFICIENCY OF INFLIXIMAB
Por: I.P. Nikishina, et al.
Publicado em: (2011-05-01)

EXPERIENCE OF TREATMENT WITH ABATACEPT IN CHILD WITH JUVENILE RHEUMATOID ARTHRITIS AND SECONDARY INEFFICIENCY OF INFLIXIMAB
Por: I.P. Nikishina, et al.
Publicado em: (2011-01-01)